The New Biotech IPO Math
Biotech IPOs are setting record valuations--the current deals average three-to-five times the previous average IPO valuations. Behind the hysteria: a new math which values biotechs not on some discount to future earnings, but on their ability to dominate new and important pharmaceutical business areas and thereby create new monopolies.
You may also be interested in...
Progress for two US-based companies in the race to develop a COVID-19 vaccine.
BeiGene's BTK inhibitor for leukemia/lymphoma and Sanofi/Genzyme's enzyme replacement therapy for MPS I among novel drugs newly approved in China.
A new document from the US FDA details acceptable substitutions for COVID-19 testing components that may be difficult to come by. See what the regulatory agency said about it here.